- Home
- NUVL vs VNT Comparison
NUVL vs VNT Comparison
Compare NUVL & VNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- VNT
- Stock Information
- Founded
- NUVL 2017
- VNT 2019
- Country
- NUVL United States
- VNT United States
- Employees
- NUVL N/A
- VNT N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- VNT Industrial Machinery/Components
- Sector
- NUVL Health Care
- VNT Industrials
- Exchange
- NUVL Nasdaq
- VNT Nasdaq
- Market Cap
- NUVL 5.6B
- VNT 5.3B
- IPO Year
- NUVL 2021
- VNT N/A
- Fundamental
- Price
- NUVL $75.00
- VNT $35.73
- Analyst Decision
- NUVL Strong Buy
- VNT Buy
- Analyst Count
- NUVL 8
- VNT 7
- Target Price
- NUVL $115.50
- VNT $44.20
- AVG Volume (30 Days)
- NUVL 452.9K
- VNT 721.3K
- Earning Date
- NUVL 08-07-2025
- VNT 07-31-2025
- Dividend Yield
- NUVL N/A
- VNT 0.28%
- EPS Growth
- NUVL N/A
- VNT N/A
- EPS
- NUVL N/A
- VNT 2.46
- Revenue
- NUVL N/A
- VNT $2,964,300,000.00
- Revenue This Year
- NUVL N/A
- VNT $2.28
- Revenue Next Year
- NUVL N/A
- VNT $5.05
- P/E Ratio
- NUVL N/A
- VNT $14.47
- Revenue Growth
- NUVL N/A
- VNT N/A
- 52 Week Low
- NUVL $55.54
- VNT $27.22
- 52 Week High
- NUVL $113.51
- VNT $41.61
- Technical
- Relative Strength Index (RSI)
- NUVL 48.73
- VNT 50.87
- Support Level
- NUVL $76.42
- VNT $35.47
- Resistance Level
- NUVL $78.94
- VNT $36.35
- Average True Range (ATR)
- NUVL 2.71
- VNT 0.64
- MACD
- NUVL -0.34
- VNT -0.19
- Stochastic Oscillator
- NUVL 31.73
- VNT 38.30
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About VNT Vontier Corporation
Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.